AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02709564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 400 sublingual
Description: patients will take 2 tablets of sublingual misoprostol 400 microgram 3 hours and 1 hour before the surgery
Study NCT02709564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo 400 sublingual
Description: patients will take 2 tablets of sublingual placebo 400 microgram 1 hour before the surgery
Study NCT04123782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: F-ESW Treatment
Description: The biological principles on which is based Focused Shockwave Treatment (F-ESWT) is has been demonstrated mostly in terms of improvement of Platelet Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), Insulin Growth Factor-1 (IGF-1) and Transforming Growth Factor b1 (TGF-b1).
Study NCT04123782 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo F-ESW Treatment
Description: Very low concentration of F-ESW.
Study NCT01856881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 876
Description: Ascending multiple doses of study drug administered SC
Study NCT01856881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 876
Description: Ascending multiple doses of study drug administered SC
Study NCT03341962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMU-838
Description: IMU-838 tablet
Study NCT03341962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets manufactured to mimic IMU-838 tablets
Study NCT01796327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacomitinib oral
Description: Dacomitinib 45 mg oral tablet
Study NCT01796327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacomitinib intravenous
Description: Dacomitinib 20 mg solution will be given as 1 hour intravenous infusion
Study NCT01963312 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial Supraselective Embolization of the prostate
Study NCT01963312 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral Resection of the prostate
Study NCT03831594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galvanic Vestibular Stimulation
Description: Electrical current (under 1.5mA) applied to the mastoid processes to stimulate the balance organs in the inner ear
Study NCT03831594 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy
Description: 45 minutes of standard physiotherapy treating impairments and functional problems
Study NCT03831594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physiotherapy
Description: 45 minutes of standard physiotherapy treating impairments and functional problems
Study NCT02866474 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: population living at home with meals on wheels
Study NCT02866474 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: population living in an EHPAD
Study NCT01081249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo then intranasal oxytocin
Description: Participant received intranasal placebo spray at first psychotherapy session, and received a single dose of 40 IU intranasal oxytocin at the second session.
Study NCT01081249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin then placebo
Description: Participant received a single dose of 40 IU intranasal oxytocin at the first psychotherapy session, and received a similar dose of intranasal placebo spray at the second session.
Study NCT00967551 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient Sprinkles with zinc
Description: Daily dose of 1 packet of sprinkles
Study NCT00967551 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micronutrient sprinkles without zinc
Description: I packet of micronutrient sprinkles without zinc
Study NCT02422212 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: patients eat a mixed solid meal
Description: The three groups were given an indirect calorimetry examination to measure their resting metabolic rate (RMR), respiratory exchange rate (RER) and DIT. The patients collected urine during 24 hours for urinary nitrogen analysis. Immediately after the RMR measurement, patients received a solid mixed meal (270 kcal, with 62% carbohydrate, 12% protein and 26% lipid). Ten minutes after beginning this food intake, postprandial (PP) energy expenditure measurements were taken in the following sequences (in minutes): 10-20, 20-30, 30-40, 60-70, 70-80, 80-90, 110-120, 120- 130, 130-140, 160-170 and 170-180.The DIT was calculated for each time interval.
Study NCT02422212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patients eat a mixed solid meal
Description: The three groups were given an indirect calorimetry examination to measure their resting metabolic rate (RMR), respiratory exchange rate (RER) and DIT. The patients collected urine during 24 hours for urinary nitrogen analysis. Immediately after the RMR measurement, patients received a solid mixed meal (270 kcal, with 62% carbohydrate, 12% protein and 26% lipid). Ten minutes after beginning this food intake, postprandial (PP) energy expenditure measurements were taken in the following sequences (in minutes): 10-20, 20-30, 30-40, 60-70, 70-80, 80-90, 110-120, 120- 130, 130-140, 160-170 and 170-180.The DIT was calculated for each time interval.
Study NCT00961220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Applied topically
Study NCT00961220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00961220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-Benzylguanine
Description: Given IV
Study NCT03027986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: postural rehabilitation program
Description: This program is based on sensory-motor control
Study NCT04267874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of nasal swabs, blood, urine, and stool
Study NCT04267874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplementation
Description: Given black raspberry nectar PO
Study NCT04267874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO
Study NCT04267874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05860075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM01
Description: IMM01 will be administered once a week for 4 weeks.
Study NCT02395926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline CR 600mg
Description: HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00
Study NCT02395926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliatilin 400mg
Description: Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00
Study NCT02395926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline CR 600mg
Description: HT-003 600mg\*2tab, administration 1 times per 1 day 8:00 a.m.
Study NCT00282334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedical blood pressure monitoring
Description: Measurement of home blood pressure, three times per week for three months and once a week for three months.
Study NCT02319421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alarm Reduction Script
Description: The intervention will consist of a script to facilitate the discussion of the alarm data that will take place on weekday mornings. The script will be used by huddle participants as a structured outline to rapidly discuss the high alarm low acuity patients eligible for intervention. The patients who are identified will have further discussion on rounds to determine if there are appropriate ways to reduce the alarm rates of individual patients through the safe adjustment of physiologic monitor parameters.
Study NCT03362970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFire Gastrointestinal Panel FilmArray®
Description: The BioFire Gastrointestinal Panel FilmArray® is a multiplexed nucleic acid (NA) based device that simultaneously identifies 22 enteric pathogens. It specifically tests for the presence of Shiga toxin and for O157. It requires 2 minutes of hands-on-time, returns results in \~2-3 hour, and is Health Canada and Food and Drug Administration approved. The device, which has been validated, hopefully will enable the early identification of infected children and initiation (or withholding) of interventions directed by previously unavailable clinical data. It will enable us to bring a precision medicine approach into ED care.
Study NCT03362970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard practices for children with hematochezia upon the discretion of the treating physician. If investigations are ordered, results have a turn-around time up to 72 hours.
Study NCT03666832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEW-7197
Description: TEW-7197 1cycle 14days~-intake 5days, rest 2days
Study NCT05752253 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Counseling
Description: Counseling is a process which, through positive orientation and the enhancement of personal resources, is aimed at promoting the improvement of the quality of life in the other.
Study NCT02728830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg IV
Study NCT02826642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDH305
Study NCT01148199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-expandable metalic stent
Description: Comparison of self-expandable metalic stent versus multiple plastic stents in post OLT biliary stenosis.
Study NCT01148199 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple plastic stents
Description: Comparison of self-expandable metalic stent versus multiple plastic stents in post OLT biliary stenosis.
Study NCT01803984 — intervention group
Intervention type: DEVICE
Intervention: MRI
Study NCT01803984 — intervention group
Intervention type: DEVICE
Intervention: EndoPAT
Description: The endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device
Study NCT01803984 — intervention group
Intervention type: OTHER
Intervention: Neuropsychological battery
Description: The cognitive status in the patient cohort will be ascertained by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
Study NCT03009214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMC303
Description: AMC303 is a CD44v6 inhibitor blocking receptor tyrosine kinase (RTK) pathways
Study NCT04723121 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Urine ELISA for immunological markers (IL-2 and IL-10)
Description: IL-2 and IL-10 levels were measured in the supernatants. Natural human-produced IL-2 and IL-10 concen¬trations were determined in the urine of all patients and controls by solid phase ELISA Quantikine IL-2 Immunoassay and IL-10 Immunoassay, respectively
Study NCT04723121 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) analysis
Description: blood samples using QIAamp® RNA Blood Mini kit (QIAGEN, USA). 1 μg of total RNA was reverse transcribed with random primers, using High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). RT-qPCR analysis was carried out with SYBER Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA). Primers for TNF-α, CTLA4, T-bet+, GATA3+, FoxP3+ and GABDH as PCR control
Study NCT03930719 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stroke screening tools
Description: Patients are evaluated for the presence of PSD using DSM-5 criteria (gold standard). Established delirium detection tools are evaluated for their diagnostic accuracy compared to the gold standard.
Study NCT01592357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Description: A short and simple 8-forms Tai Chi routine will be used in this study. This routine has been previously standardized and field tested. Participants will be coached, by a certified Tai Chi instructor, in practicing the proper mechanics of executing each of the eight physical movements comprising the 8-forms of Tai Chi. A brief 5 minute period of walking calisthenics pertinent to Tai Chi movements, postures and diaphragmatic breathing will take place before training to warm up and after training to cool down. The Tai Chi training will be 2 times a week and the total exercise time, including warm-up and cool down, will be 50 minutes for each session. Over a period of 12 weeks, the participants will learn all 8-forms and continue practicing them for the final 12 weeks of the training period.
Study NCT01592357 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Exercise
Description: The sham exercise (control) group will be involved in low-intensity stretching exercises two times per week. These exercises will be designed as a sham exercise condition. A brief 5 minute period of walking will take place before the sham exercise to warm up and after the sham exercise to cool down. Sham exercise sessions will include stretching exercises of the neck, trunk and extremities. The total exercise time for the sham exercise group will be 50 minutes and participants will meet 2 times per week for a period of 24 weeks.
Study NCT01916954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3-day artemether-lumefantrine
Study NCT01916954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-day artemether-lumefantrine
Study NCT02592798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept IV administered on Day 1, 15, 29 and then every 28 days
Study NCT02592798 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline administer on Day 1, 15, 29 and then every 28 days
Study NCT02592798 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: D5W
Description: Dextrose 5% in Water (D5W) administered on Day 1, 15, 29 and then every 28 days
Study NCT02379663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Rivaroxaban was taken orally in a dosage of 10mg once daily
Study NCT02379663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin was injected subcutaneously in a dosage of 40mg once daily
Study NCT02379663 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: subcutaneous injection of 1 cc of normal saline once daily
Study NCT04204889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaloacetic Acid
Description: The first 3 patients will receive 500 mg twice daily, and subsequent cohorts will increase by 500 mg per dose to a maximum of 2500 mg twice daily.
Study NCT02233517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy provides patients with the skills to 1) identify and challenge maladaptive cognitions that are contributing to self-destructive behaviors; and 2) implement techniques such as relaxation training, communication skills, and relaxation training to address physiological and environmental barriers to effective functioning.
Study NCT02233517 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Therapy
Description: Present Centered Therapy utilizes interpersonal process, supportive techniques, identification of response options, encouragement of adaptive reactions, and focus on the here-and-now to support patients in their efforts to improve functioning.
Study NCT00942604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEP005 (ingenol mebutate) Gel
Description: two day treatment
Study NCT01144663 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menjugate®
Description: 3-dose intramuscular injection
Study NCT01144663 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NeisVac-CTM
Description: 3-dose intramuscular injection
Study NCT01144663 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ hexa
Description: 4-dose intramuscular injection
Study NCT00942604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: two day treatment
Study NCT02725918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2,iv,d1,q3w,until PD
Study NCT01144663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™ hexa
Description: 4-dose intramuscular injection
Study NCT01144663 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix™
Description: 4-dose intramuscular injection
Study NCT01144663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix™
Description: 4-dose intramuscular injection
Study NCT02725918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m2,iv,d1,q3w,until PD
Study NCT02725918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m2,iv,d1,q3w,×4 cycles
Study NCT04601961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Monitoring and other anaesthetic procedures including the management of hypertension and hypotension will be the same as SEVO group. Induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Sevoflurane will not be used, and oxygen and air would be given to provide a FiO2 of 30-50%.~Target controlled infusion (TCI) with a modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia and titrated to effect. The usual effect site concentration is 1.5-3 mcg.ml-1 and BIS monitoring will also be used to produce a value of between 40-60. As with patients in the SEVO group, remifentanil will be infused at a rate of between 0.1-0.3 mcg.kg.min-1.
Study NCT04601961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously for induction of general anaesthesia. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to maintain a BIS value of between 40-60. Intravenous remifentanil infusion between 0.1-0.2 mcg/kg/min will be given and this will be titrated to provide optimal haemodynamic parameters.
Study NCT03773276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine boluses
Description: On portal vein declamping, We will inject NE boluses in the C.V.P port of the pulmonary artery catheter with 5 ml saline flushing after each. After reperfusion, we will start bolus noradrenaline 20 µg if mean arterial blood pressure (mABP) decreases by 10 % or more of the basal reading (immediately before portal vein declamping after ensuring withholding of the surgical manipulation). Additional NE boluses will be given as follow;~* If mABP rises to 65 mmHg (lowest target level), we will hold NE boluses.~* If mABP remains constant or begins to rise but did not reach 65 mmHg, we will give 20 µg after 10 seconds from the previous bolus~* If mABP continues to drop, we will add 10 µg to the previous dose after 10 seconds and can be repeated.~* If mABP remains below 65 mmHg more than 1 minute, we will give the scheduled bolus NE with adding 10 µg adrenaline boluses.
Study NCT02902237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tTF-NGR
Description: tTF-NGR will be given as 1-hour infusion via central venous access once daily for 5 days with a subsequent rest period of 2 weeks and following cycles with dose escalation of 0.5 mg/m2 upon judgement of tolerability and therapeutic activity. Starting dose will be 1 mg/m2/day. Dose-escalation is stopped before the maximum number of 8 escalation steps if tumor response, tumor progression or a Dose-Limiting Toxicity (DLT) is observed.
Study NCT01327482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Dosage: 400mg/PO (by mouth) Frequency: Twice daily Duration: During course of menstrual cycle (28 days)
Study NCT02187042 — intervention group
Intervention type: OTHER
Intervention: Best supportive care
Description: BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
Study NCT03641586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-283
Study NCT02187042 — intervention group
Intervention type: OTHER
Intervention: call center
Description: Nurses from a call center will call the patients at regular time to help patients in the management of their cancer, with some dietetic advices, medical advices etc.
Study NCT03164395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal Cardioversion
Description: Internal Cardioversion with device maximum output shock from RV coil to Can versus external cardioversion per institutional protocol
Study NCT03164395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External Cardioversion
Description: External Cardioversion per institutional protocol
Study NCT01399164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 14C-B12 fortified bread
Description: A single serving of 14C-B12 fortified bread